GlassScriptPhysician profile
Cheston M Reed
NPI 1174633515
$2,174.23
in general payments reported to CMS, 2019-2025
27 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $335 · 2021: $588 · 2022: $465 · 2023: $236 · 2024: $234 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $574.16 | 2019-2024 | |
| Daiichi Sankyo INC. | $208.91 | 2019-2024 | Injectafer |
| Exeltis, USA INC. | $149.33 | 2019-2024 | Slynd |
| Myovant Sciences INC. | $142.61 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.10 | 2021-2024 | |
| Mylan Pharmaceuticals INC. | $92.97 | 2019-2022 | |
| Scynexis, INC. | $91.85 | 2022 | |
| Mayne Pharma Commercial LLC | $79.74 | 2022-2025 | |
| Pfizer INC. | $75.82 | 2019-2023 | |
| Novo Nordisk INC | $73.05 | 2021-2022 | |
| Astellas Pharma US INC | $65.03 | 2023-2024 | Veozah |
| Bausch Health US, LLC | $61.19 | 2020-2021 | |
| Therapeuticsmd, INC. | $60.04 | 2019-2022 | |
| Amgen INC. | $48.74 | 2019-2021 | |
| Shield Therapeutics INC | $43.22 | 2023-2024 | Accrufer |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $36.79 | 2024-2025 | Paragard T 380a |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.85 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $31.25 | 2023 | Myfembree |
| Pacira Pharmaceuticals Incorporated | $28.76 | 2024 | Exparel |
| Medtronic, INC. | $28.24 | 2023 | Truclear |
| Avion Pharmaceuticals | $25.04 | 2020-2021 | |
| Biogen, INC. | $23.93 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $23.21 | 2024 | Omni Hysteroscope, Acessa Provu System, Novasure |
| Organon LLC | $23.16 | 2025 | Nexplanon |
| Millicent US INC | $14.94 | 2025 | Femlyv, Intrarosa |
| Ascend Therapeutics US, LLC | $13.16 | 2021 | |
| Evofem Biosciences, INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheston Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.